Bringing to Light the Risk Factors And Incidence of Neuropsychological Dysfunction in ICU Survivors, 2nd Study
NCT ID: NCT04305600
Last Updated: 2025-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
567 participants
OBSERVATIONAL
2020-10-01
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The BRAIN Intensive Care Unit (ICU) Study: Bringing to Light the Risk Factors
NCT00392795
Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study
NCT03098459
Simultaneous Recumbent Cycling and Cognitive Training
NCT04556227
A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
NCT06411561
Pilot Study of Early Cognitive Training in the Intensive Care Unit
NCT03284437
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Our NIA-funded, NEJM published, PAR-18-029 cited original BRAIN-ICU-1 Study10,14 of 821 subjects showed over one-third of ICU survivors (without preexisting dementia) emerged with new ADRD by 1 year.10-12,17,19,24-27 Our pilot data found that many patients have a progressive ADRD phenotype. Some demonstrated transient decline followed by cognitive recovery. Our limited work indicates that cognitive rehabilitation may induce recovery,28 but we must discover which ADRD phenotypes are responsive to intervention.29,30 We must understand neurodegenerative and pathoanatomic risk factors for ADRD in survivors. Our pilot MRI data show acute ICU delirium is associated with atrophy of the whole brain, frontal lobes, and hippocampus.21,22 Specifically, a higher ventricle-to-brain ratio (VBR) appears linked with ADRD.20 We lack information on neuroinflammation, microvascular injury, white matter disease, and amyloid/tau-related neurodegeneration pathways.
In ICU survivors with/without delirium, the BRAIN-ICU-2 Study will define phenotypes, risk factors, diagnostics, mechanistic pathways, and histopathology of ADRD (in direct response to PAR-18-029). We will characterize which patients show cognitive reserve, recovery, and ADRD progression, and in so doing, address knowledge gaps between delirium and ADRD and facilitate future interventions.
Our overarching hypothesis:
Delirium results in neurodegenerative and neuropathological changes that can be measured with imaging biomarkers, plasma/cerebrospinal fluid (CSF) biomarkers, and autopsy measures of neuropathology, all of which ultimately drive post-ICU ADRD phenotypes, which we will characterize in BRAIN-ICU-2.
1.2. Specific Aims (Figure 1) Aim 1: To test the hypothesis that ICU survivorship and mortality over a decade is associated with unique clinical ADRD phenotypes. With our extended BRAIN-ICU-1 and new cohort (with/without delirium), we will amass survivor follow-up data at 3mo \& 12mo (original + new cohort, below), 4y \& 6y (completed), and now 12-14y data. Clinical ADRD Consensus Diagnosis will include Repeatable Battery for Assessment of Neuropsychological Status (RBANS) 31-33, and tests of memory, executive function, functional outcomes, \& quality of life. We will conduct trajectory analyses to define phenotypes (reserve, recovery, progression).
Aim 2: To test the hypothesis that global brain atrophy as assessed by structural MRI will mediate the association between delirium duration and clinical ADRD phenotypes at 12-month follow-up. We will enroll a new ICU cohort of 567 patients from Vanderbilt \& Rush and engage 3mo \& 12mo ADRD follow-up. In-hospital, we will assess delirium (Confusion Assessment Method-ICU), baseline risk (e.g., education, frailty, comorbidity, ApoE), neuroinflammatory plasma biomarkers (e.g., HMGB1, S100B, PAI-1), and clinical risks (e.g., sepsis, drug exposures, immobility). In addition to enrollment MRIs, we will also obtain 3T MRI, plasma, and CSF biomarkers at discharge and 12-month. Our primary analysis will assess if the change in ventricle-to-brain ratio (VBR) mediates the association between delirium and clinical ADRD. Secondary analyses will evaluate MRI measures of brain structure (white matter integrity) \& function (perfusion), and plasma/CSF biomarkers for AD neuropathology, inflammation, \& synaptic/axonal integrity as additional mediating paths.
Aim 3: To test the hypothesis that microvascular pathology underlies post-ICU ADRD. We will establish a repository at Rush and analyze decedents' brains from both the extended BRAIN-ICU-1 and new ICU cohort. We will assess the association between delirium and autopsy measures of neuropathology focusing on cerebrovascular disease (e.g., microinfarcts due to endothelial activation in sepsis). We will also fully characterize the presence of other common neuropathologies (e.g., plaques, tangles, TDP-43).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aim 1
Aim 1 participants will be recruited from participants in the first BRAIN study at VUMC.
No interventions assigned to this group
Aim 2
Aim 2 participants will be recruited from the ICU populations at both VUMC and RUMC.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* shock (e.g., with vasopressors,
* intra-aortic balloon pump,
* Extracorporeal Membrane Oxygenation therapy) and/or
* respiratory failure \[e.g., on mechanical ventilation or non-invasive positive pressure ventilation (NIPPV)\]
Exclusion Criteria
2. Cumulative ICU time \> 5 days in the past 30 days, prior to this hospitalization
3. Inability to start the informed consent process within the 72 hours following organ failure:
* Attending physician refusal
* Patient and/or surrogate refusal
* 72-hour period of eligibility was exceeded before the patient was screened
* Patient unable to consent and no surrogate available within the 72-hour period
4. Residence \> 100 miles from study site and do not regularly visit the area.
5. Patients who are homeless and have no secondary contact person available.
6. Cardiac surgery within the current hospitalization
7. Dementia or other chronic neurologic disease or disorder that either makes the patient incapable of living independently at baseline or results in an IQCODE \>3.8(completed by the patient or their qualified surrogate). (Examples include but are not limited to mental illness requiring long-term institutionalization, acquired or congenital mental retardation, Parkinson's disease, Huntington's disease, severe Alzheimer's disease or dementia of any etiology, and debilitating cerebrovascular disease.)
8. Acute or subacute neurologic deficit that is expected to make the patient incapable of living independently after hospital discharge due to cognitive deficits. (Examples include, but are not limited to stroke, intracranial hemorrhage, cranial trauma, intracranial malignancy, anoxic brain injury, and cerebral edema.)
9. Inability to understand English or Spanish or bilateral deafness or bilateral vision loss
10. Current enrollment in a study that does not allow co-enrollment
11. Prisoners
12. Active substance abuse or psychotic disorder (e.g., schizophrenia or schizo-affective disorder) or recent (within the past 2 years) serious suicidal gesture necessitating hospitalization.
13. Expected death within 12 hours of enrollment or lack of commitment to treatment by family or the medical team (e.g., likely to withdraw life support measures within 12 hours of enrollment)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
Vanderbilt University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wes Ely
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
E. Wesley Ely, MD
Role: PRINCIPAL_INVESTIGATOR
VUMC
Mayur Patel, MD
Role: PRINCIPAL_INVESTIGATOR
VUMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rush University Medical Center
Chicago, Illinois, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRAIN-ICU-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.